China NMPA approves Phase II trial of Ascletis acne therapy drug ASC40
Category: #healthcare  By Mateen Dalal  Date: 2021-08-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

China NMPA approves Phase II trial of Ascletis acne therapy drug ASC40

Chinese biotechnology company Ascletis Pharma Inc. has announced that China NMPA (National Medical Products Administration) recently approved the Phase II clinical trial of ASC40 for patients suffering from acne vulgaris.

According to reliable sources, 180 patients will participate in the phase II trial which will be double-blind, and placebo-controlled. They will be assigned to one of the four groups randomly (25 mg, 50 mg, 75mg, placebo).

The trial will allow researchers to assess the efficacy and safety of ASC40 for the treatment of patients suffering from moderate to severe acne.

For the record, acne vulgaris is a medical condition that affects 640 million people worldwide and is the eighth most common disease in the world. The onset of the condition often happens during puberty. Approximately 85% of young adults and adolescents aged between 12-25 years suffer from acne currently.

FASN (fatty acid synthase) is a crucial enzyme that is known to regulate de novo lipogenesis. Production of human sebum primarily requires de novo lipogenesis, which shoots up due to acne and is suppressed by ASC40, a FASN inhibitor.

Dr. Jinzi.J.Wu, Chairman, Founder, and CEO of Ascletis Pharma was quoted saying that the Phase II study will be the second clinical trial using ASC40 approved by China NMPA this month.

He further added that this study has shown that lipid metabolism plays a vital role in various disease areas and is the third indicator for ASC40 following recurrent glioblastoma (GBM), and non-alcoholic steatohepatitis (NASH).

Notably, the global acne medication market was assessed at USD 11.86 billion in 2019 and is estimated to be worth USD 13.35 billion by 2027. First-line treatments for acne vulgaris currently include topical retinoids, oral isotretinoin, antibiotics, and androgen receptor inhibitor.

Source Credits---

https://www.prnewswire.com/news-releases/china-nmpa-approves-phase-ii-clinical-trial-of-asc40-for-the-treatment-of-patients-with-acne-301350772.html

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Canada to invest $708 Mn to develop new nuclear power technology
Canada to invest $708 Mn to develop new nuclear power technology
By Mateen Dalal

Canada would invest $708 million (CAD 970 million) for the development of a grid-scale small modular...

Rockefeller Foundation donates $15Mn to fight AIDS, TB & Malaria
Rockefeller Foundation donates $15Mn to fight AIDS, TB & Malaria
By Mateen Dalal

The Rockefeller Foundation has reportedly announced that it intends to donate $15 million to the Glo...

Meta settles Facebook’s location tracking lawsuit at USD 37.5 million
Meta settles Facebook’s location tracking lawsuit at USD 37.5 million
By Mateen Dalal

According to recent court documents, Facebook parent Meta has settled worth USD 37.5 million for a l...